Key Takeaways
- • Healthcare private equity activity is recovering despite Q2 slowdown caused by geopolitical uncertainty and macroeconomic headwinds; deal processes were delayed rather than abandoned, with transactions resuming as market conditions stabilize.
- • European healthcare assets are attracting increased capital from US and international PE firms seeking stable investment opportunities outside home markets, while portfolio rebalancing from underperforming software sector is driving additional healthcare fund interest.
- • US Most-Favoured Nation (MFN) drug pricing policy is reshaping pharmaceutical M&A strategy, with biotech companies reassessing or shelving European product launches due to concerns that lower regional prices could trigger revenue erosion under MFN provisions linking US prices to international benchmarks.
- • Preventive healthcare, outpatient services, and consumer health segments are positioned for structural growth and represent primary focus areas for PE investors according to Rothschild & Co's assessment at the IIH Private Capital conference.
Summary
Healthcare remains one of the most attractive sectors for private equity investment despite near-term macroeconomic headwinds, according to remarks from Rothschild & Co's healthcare team at the Investors in Healthcare Private Capital conference on July 13, 2026. While geopolitical uncertainty in the Middle East and subdued broader M&A markets slowed deal processes during the second quarter, the speakers characterized the slowdown as a temporary delay in transaction velocity rather than a fundamental loss of investor appetite. Deal processes "didn't fall over completely, they just started going pretty slowly," according to the bank's assessment, with activity already beginning to recover.
Recent geopolitical uncertainty has catalyzed a notable shift in international capital deployment. European healthcare assets are attracting a growing share of investment from US and international private equity firms seeking stable opportunities outside their home markets. Simultaneously, subdued activity in the software sector has prompted many global buyout funds to rebalance their portfolios, creating additional capital seeking exposure to healthcare assets. This combination of flight-to-quality behavior and tactical reallocation is supporting deal momentum in the healthcare sector.
A significant emerging theme affecting M&A strategy is the impact of the US administration's Most-Favoured Nation (MFN) pricing policy, which links US drug prices more closely to those paid in other developed markets. According to Rothschild & Co, this policy is already influencing strategic decisions across the pharmaceutical industry. US and European biotechnology companies are reassessing or even shelving plans to launch products in Europe, recognizing that lower European prices could ultimately affect US revenues under MFN provisions. The result is a more complex M&A environment with increased strategic uncertainty around cross-border pharmaceutical transactions.
Within healthcare, specific subsectors are positioned for structural growth and PE investor focus. Preventive healthcare, outpatient services, and consumer health segments are expected to benefit from demographic and policy tailwinds, representing priority areas for value creation strategies among PE investors in the sector.
Recent geopolitical uncertainty has catalyzed a notable shift in international capital deployment. European healthcare assets are attracting a growing share of investment from US and international private equity firms seeking stable opportunities outside their home markets. Simultaneously, subdued activity in the software sector has prompted many global buyout funds to rebalance their portfolios, creating additional capital seeking exposure to healthcare assets. This combination of flight-to-quality behavior and tactical reallocation is supporting deal momentum in the healthcare sector.
A significant emerging theme affecting M&A strategy is the impact of the US administration's Most-Favoured Nation (MFN) pricing policy, which links US drug prices more closely to those paid in other developed markets. According to Rothschild & Co, this policy is already influencing strategic decisions across the pharmaceutical industry. US and European biotechnology companies are reassessing or even shelving plans to launch products in Europe, recognizing that lower European prices could ultimately affect US revenues under MFN provisions. The result is a more complex M&A environment with increased strategic uncertainty around cross-border pharmaceutical transactions.
Within healthcare, specific subsectors are positioned for structural growth and PE investor focus. Preventive healthcare, outpatient services, and consumer health segments are expected to benefit from demographic and policy tailwinds, representing priority areas for value creation strategies among PE investors in the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.